Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
OTL78 Shows Safety, Feasibility in PSMA+ Prostate Cancer Detection
April 20th 2023OTL78 appears to help in identifying prostate tumors, surgical margins, residual disease in the resection bed, and nodal metastases during PSMA-targeted fluorescence-guided surgery in those with PSMA-positive prostate cancer.
FDA Approves Polatuzumab Vedotin/R-CHP Combo in Previously Untreated DLBCL
April 19th 2023Patients with previously untreated diffuse large B-cell lymphoma can now receive polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone following the FDA’s approval of the regimen.
HSCT During First CR Yields Non-Superior OS vs Consolidation Chemo in AML
April 19th 2023Despite an improvement in disease-free survival, patients 60 years or over with acute myeloid leukemia do not appear to have a survival benefit from allo-HCT during first complete remission compared with consolidation chemotherapy.
HRQOL Data Support Pembrolizumab/Chemo in Recurrent/Metastatic Cervical Cancer
April 14th 2023Adding pembrolizumab to chemotherapy with or without bevacizumab can help patients with persistent, recurrent, or metastatic cervical cancer “live longer and better,” according to an expert from the University of Arizona College of Medicine.
Hormone Therapy/Radiation Improves PFS in Oligometastatic Prostate Cancer
April 13th 2023In addition to the benefit seen with hormone therapy plus metastasis-directed radiation in oligometastatic prostate cancer, use of intermittent hormone therapy may result in positive disease control and longer eugonadal testosterone intervals.
FDA Pauses Trial Evaluating MT-0169 in R/R Multiple Myeloma and Lymphoma
April 11th 2023Investigators behind a phase 1 trial investigating MT-0169 in relapsed or refractory multiple myeloma and non-Hodgkin lymphoma will pause enrollment of new patients following prior reports of cardiac adverse effects in 2 patients.
Allele Fractions Reliable Surrogate for Tumor Burden Following BRAFi in CRC
April 6th 2023Progression-free survival and overall survival appear to be worse in patients with metastatic colorectal cancer who have a high- vs low-BRAF allele fraction after treatment with a BRAF inhibitor plus an anti-EGFR agent plus or minus a MEK inhibitor.
Real-World Data Highlight Need for Clinically Practical MCL Therapies
April 5th 2023Retrospective data encourage further exploration of non-ASCT regimens in younger patients with mantle cell lymphoma, while maintenance rituximab should be considered following first-line therapy with bendamustine plus rituximab.